Menu
US
Shop
Request a Quote
Contact Us
US
Article

Selective targeting of mHTT presents novel therapeutic approach to huntington's disease

selective-targeting512

Huntington’s disease (HD) is a fatal neurodegenerative disorder that affects around 30,000 people in the US, with another 200,000 at risk of developing the condition. Despite extensive research into HD, there are currently no approved disease-modifying therapies available. Researchers from CHDI Foundation and Sangamo Therapeutics believe the ideal therapeutic will be one that eliminates the expression of mHTT without interfering with normal HTT function. In an effort to do just that, they have engineered zinc finger protein transcription factors (ZFP-TFs) to target the pathogenic CAG repeat and selectively lower mHTT as a therapeutic strategy. Read more about their research efforts.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Selective targeting of mHTT presents novel therapeutic approach to huntington's disease

Download Article